Cargando…

Study Protocol for Pleiotropic Effects and Safety of Sodium–Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

INTRODUCTION: Clinicopathological analyses revealed that reduction in HbA1c and use of insulin independently contribute to reduction in liver fibrosis scores during the course of nonalcoholic fatty liver disease (NAFLD) development. We will test our hypothesis that lowering glucose and increasing in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeshita, Yumie, Kanamori, Takehiro, Tanaka, Takeo, Kaikoi, Yuka, Kita, Yuki, Takata, Noboru, Iida, Noriho, Arai, Kuniaki, Yamashita, Tatsuya, Harada, Kenichi, Gabata, Toshifumi, Nakamura, Hiroyuki, Kaneko, Shuichi, Takamura, Toshinari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995806/ https://www.ncbi.nlm.nih.gov/pubmed/31956961 http://dx.doi.org/10.1007/s13300-020-00762-9

Ejemplares similares

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
por: Takeshita, Yumie, et al.
Publicado: (2022)

Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
por: Takeshita, Yumie, et al.
Publicado: (2020)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial
por: Matsushima, Yukiko, et al.
Publicado: (2016)

Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes
por: Kanamori, Takehiro, et al.
Publicado: (2018)

Nutrigenetic Interaction Between Apolipoprotein C3 Polymorphism and Fat Intake in People with Nonalcoholic Fatty Liver Disease
por: Yamamoto, Reina, et al.
Publicado: (2023)

Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients: Tight glycemic control, rather than weight reduction, ameliorates liver fibrosis
por: Hamaguchi, Erika, et al.
Publicado: (2010)

Fat‐free mass and calf circumference as body composition indices to determine non‐exercise activity thermogenesis in patients with diabetes
por: Isobe, Yuki, et al.
Publicado: (2015)

Bending of a vertical cannula without alarm during insulin pump therapy as a cause of unexpected hyperglycemia: A Japanese issue?
por: Kuroda, Kaori, et al.
Publicado: (2015)

Somatostatin Receptor-negative and Fluorodeoxyglucose-positron Emission Tomography-positive Lung Neuroendocrine Tumor G1 Exhibiting Cyclic Cushing's Syndrome
por: Nomura, Chiaki, et al.
Publicado: (2022)

Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
por: Takeshita, Yumie, et al.
Publicado: (2022)

Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
por: Takeshita, Yumie, et al.
Publicado: (2022)

Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease
por: Kawaguchi, Kazunori, et al.
Publicado: (2021)

Ectopic Fat Accumulation and Distant Organ-Specific Insulin Resistance in Japanese People with Nonalcoholic Fatty Liver Disease
por: Kato, Ken-ichiro, et al.
Publicado: (2014)

Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population
por: Oo, Swe Mar, et al.
Publicado: (2018)

Weight-adjusted lean body mass and calf circumference are protective against obesity-associated insulin resistance and metabolic abnormalities
por: Takamura, Toshinari, et al.
Publicado: (2017)

Corrigendum to ‘Weight-adjusted lean body mass and calf circumference are protective against obesity-associated insulin resistance and metabolic abnormalities’
por: Takamura, Toshinari, et al.
Publicado: (2017)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
por: Takata, Tomoaki, et al.
Publicado: (2021)

Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis
por: Kita, Yuki, et al.
Publicado: (2012)

Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease
por: Kato, Ken-ichiro, et al.
Publicado: (2015)

LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH
por: Takata, Noboru, et al.
Publicado: (2021)

Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Alcohol Intake Is Associated With Elevated Serum Levels of Selenium and Selenoprotein P in Humans
por: Isobe, Yuki, et al.
Publicado: (2021)

Corrigendum: Alcohol Intake Is Associated With Elevated Serum Levels of Selenium and Selenoprotein P in Humans
por: Isobe, Yuki, et al.
Publicado: (2021)

Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy
por: Takazakura, Akiko, et al.
Publicado: (2015)

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
por: Shima, Kosuke Robert, et al.
Publicado: (2018)

Inverse Correlation between Serum Levels of Selenoprotein P and Adiponectin in Patients with Type 2 Diabetes
por: Misu, Hirofumi, et al.
Publicado: (2012)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
por: Xie, Yan, et al.
Publicado: (2021)

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019)

A novel PHEX mutation associated with vitamin D-resistant rickets
por: Sako, Saori, et al.
Publicado: (2019)

Proteasome Dysfunction Mediates Obesity-Induced Endoplasmic Reticulum Stress and Insulin Resistance in the Liver
por: Otoda, Toshiki, et al.
Publicado: (2013)

Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma
por: Iida, Noriho, et al.
Publicado: (2019)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
por: Rastogi, Anjay, et al.
Publicado: (2023)

Eight-year longitudinal study of whole blood gene expression profiles in individuals undergoing long-term medical follow-up
por: Sakai, Yoshio, et al.
Publicado: (2021)

Severity Indices for Obstructive Sleep Apnea Syndrome Reflecting Glycemic Control or Insulin Resistance
por: Isobe, Yuki, et al.
Publicado: (2019)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2uqsa86hoqg5o9grttc8gp3ub0